In addition to NSCLC patients, cases of RET fusion-positive medullary thyroid cancer and sarcoma patients experiencing tumor regression with neoadjuvant selpercatinib treatment have been reported, which further underline the rationale to implement selpercatinib in early stages.[16–18]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.